Autopsy report · NCT00766337
Phase 2 Study of an Ocular Sirolimus (Rapamycin) Formulation in Combination With Lucentis® in Patients With Age-Related Macular Degeneration
Cause of deathNo reason given
Life of this trial
- Registered 2 months before it started.
- Ran for about 1 year 3 months before it stopped.
- 62 participants enrolled.
- No results are posted on the registry.
Vital statistics
- Status
- Terminated
- Phase
- Phase 2
- Sponsor
- Santen Inc.
- Sponsor type
- Industry
- Conditions
- Age-Related Macular Degeneration; Choroidal Neovascularization
- Interventions
- Sirolimus in combination with ranibizumab; Sirolimus in combination with ranibizumab; Placebo in combination with ranibizumab
- Participants
- 62
- Sites
- 1
- Countries
- United States
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.